AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Short Term Debt

Last Annual Value

588.00K

3-Year CAGR

%

5-Year CAGR

-25%

10-Year CAGR

-16%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Short Term Debt

SPRY · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
588.00K
35.4%-29.9%N/A 
547.00K
N/AN/AN/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
7.00K
N/A-75.7%N/A
1.28M
N/AN/AN/A
202.00K
N/A-28.1%N/A
0.00
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
472.00K
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07